Advertisement

Advertisement

ADVERTISEMENT

Videos

Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Videos

Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer

02/25/2021

Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.

Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.

Stephen Freedland, MD, discusses...

02/25/2021

Journal of Clinical Pathways

Hospital Efficiency Impact on Quality of Prostate Cancer Care

Videos

Hospital Efficiency Impact on Quality of Prostate Cancer Care

02/24/2021

02/24/2021

Journal of Clinical Pathways

Definitive vs Conservative Treatments for Older Men With Prostate Cancer

Videos

Definitive vs Conservative Treatments for Older Men With Prostate Cancer

02/24/2021

02/24/2021

Journal of Clinical Pathways

Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC

Videos

Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC

02/23/2021

02/23/2021

Journal of Clinical Pathways

Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists

Videos

Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists

02/21/2021

02/21/2021

Journal of Clinical Pathways

Researchers Identify Molecular Determinants of Apalutamide Response in Nonmetastatic CRPC

Videos

Researchers Identify Molecular Determinants of Apalutamide Response in Nonmetastatic CRPC

02/21/2021

02/21/2021

Journal of Clinical Pathways

Clinician-Facing Decision Tool to Promote Access to Prostate Cancer Clinical Trials

Videos

Clinician-Facing Decision Tool to Promote Access to Prostate Cancer Clinical Trials

02/19/2021

02/19/2021

Journal of Clinical Pathways

Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma

Videos

Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma

02/19/2021

Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.

Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.

Shilpa Gupta, MD, discusses the...

02/19/2021

Journal of Clinical Pathways

Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost

Videos

Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost

02/19/2021

02/19/2021

Journal of Clinical Pathways

Reductions in PSA Screening Associated With Increased Incidence of Prostate Cancer in US

Videos

Reductions in PSA Screening Associated With Increased Incidence of Prostate Cancer in US

02/19/2021

02/19/2021

Journal of Clinical Pathways

Specialties

Prostate Cancer

JCP May/June 2024 Issue

Current Issue

June 2024

Volume 10

Issue 3

More Content

Blogs

Popular Articles

Conference Coverage

American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

05/31/2016

Its once again time for the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2016; Chicago, IL), which will bring together more than 30,000 oncology professionals from around the world to...

Its once again time for the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2016; Chicago, IL), which will bring together more than 30,000 oncology professionals from around the world to...

Its...

05/31/2016

Journal of Clinical Pathways

Editor's Page

For Buy-In of the Clinical Pathways Concept, Transparency Is Key

05/06/2016

Winston Wong, PharmD, Editor-in-Chief

Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...

Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...

...

05/06/2016

Journal of Clinical Pathways

Pharma Insights

When Medication Price Deflates Perception of Therapeutic Effect

04/11/2016

Larry Blandford, PharmD—Column Editor

Stephen C Carter

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

...

04/11/2016

Journal of Clinical Pathways

Research in Review

Report Outlines the Path to Improving Biomarker Tests for Targeted Therapies

03/21/2016

JCP Editors

Biomarker tests are not being adequately used in clinical practice due to a lack of common evidentiary standards for regulatory, reimbursement, and clinical decisions regarding their use, according to a report by the...

Biomarker tests are not being adequately used in clinical practice due to a lack of common evidentiary standards for regulatory, reimbursement, and clinical decisions regarding their use, according to a report by the...

...

03/21/2016

Journal of Clinical Pathways

Research in Review

Costs for High-Risk Patients With ALL Increasing

02/25/2016

JCP Editors

Costs for high-risk pediatric and adolescent patients with acute lymphoblastic leukemia (ALL) may be higher than standard-risk patients with the disease, according to a recent study. While data regarding health care...

Costs for high-risk pediatric and adolescent patients with acute lymphoblastic leukemia (ALL) may be higher than standard-risk patients with the disease, according to a recent study. While data regarding health care...

Costs...

02/25/2016

Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement